BACKGROUND: Liver biopsy is the reference standard for diagnosing the extent of fibrosis
in chronic liver disease; however, it is invasive, with the potential for serious complications …

People who inject drugs (PWID) represent the core of the hepatitis C virus (HCV) epidemic
in many countries and HCV-related disease burden continues to rise. There are compelling …

Hepatic fibrosis is a common pathway leading to liver cirrhosis, which is the end result of any
injury to the liver. Accurate assessment of the degree of fibrosis is important clinically …

Background: Chronic hepatitis C virus is difficult to treat and affects approximately 3 million
Americans. Protease inhibitors increase the effectiveness of standard therapy, but they are …

Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease and
complications can occur in patients with sustained virologic response (SVR) with residual …

Background & Aims Hepatitis C (HCV) is a common cause of chronic liver disease
worldwide. Current standard treatment for genotype-1 patients uses a triple combination of …

Assessment of liver fibrosis in chronic hepatitis C virus (HCV) infection is considered a
relevant part of patient care and key for decision making. Although liver biopsy has been …

Background: Prevalence of chronic hepatitis C virus (HCV) infection is high among
incarcerated persons in the United States. New, short-duration, high-efficacy therapies may …

In the developed world, the majority of new and existing hepatitis C virus (HCV) infections
occur among people who inject drugs (PWID). The burden of HCV-related liver disease in …

The assessment of the fibrotic evolution of chronic hepatitis has always been a challenge for
the clinical hepatologist. Over the past decade, various non-invasive methods have been …